Denali Therapeutics once again touted biomarker data for its experimental Hunter syndrome drug Tuesday morning, aiming to push the program toward FDA approval after disappointing Wall Street two years ago.
The biotech revealed that 13 patients who had received the drug, dubbed DNL310, for at least two years saw an average 64% reduction in serum neurofilament. Additionally, in 11 evaluable patients at the two-year mark, Denali observed an average 53.5% reduction in cerebrospinal fluid neurofilament.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters